AIGH Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

AIGH Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-607	Closed	-$334K	–	59
2022 Q4	$334K	Hold	607	–	–	0.11%	45
2022 Q3	$686K	Hold	607	–	–	0.21%	40
2022 Q2	$853K	Hold	607	–	–	0.22%	40
2022 Q1	$915K	Hold	607	–	–	0.22%	39
2021 Q4	$1.49M	Sell	607 -167	-22%	-$517K	0.45%	40
2021 Q3	$3.32M	Hold	774	–	–	0.7%	33
2021 Q2	$3.17M	Hold	774	–	–	0.57%	34
2021 Q1	$4.01M	Buy	+774	New	+$3.61M	0.84%	32

Other funds holding PCSA

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIGH Capital Management's PCSA Position: Q1 2023 in Review

AIGH Capital Management sold out of Processa Pharmaceuticals (PCSA) in Q1 2023, closing a stake of 607 shares — an estimated $334K sold.

AIGH Capital Management first reported a position in PCSA in Q1 2021 and held it in 8 quarters. The position peaked at $4.01M in Q1 2021. 22 funds tracked by Wall St. Rank hold PCSA as of Q1 2023.

AIGH Capital Management reported no remaining Processa Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
AIGH Capital Management sold 607 Processa Pharmaceuticals shares in Q1 2023, an estimated $334K.
AIGH Capital Management first reported a position in Processa Pharmaceuticals in Q1 2021 and held it in 8 quarters.
AIGH Capital Management's Processa Pharmaceuticals position peaked at $4.01M in Q1 2021.
22 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2023.

Based on AIGH Capital Management's 13F filing for Q1 2023, filed 15 May 2023.